MD-1100 Acetate
Protocol MCP-103-005
Phase 2 small_molecule completed
Quick answer
MD-1100 Acetate for Irritable Bowel Syndrome is a Phase 2 program (small_molecule) at IRONWOOD PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- IRONWOOD PHARMACEUTICALS INC
- Indication
- Irritable Bowel Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed